ENTA is where it is They are on the cusp of big breakthroughs. ENTA went up 28% the day before yesterday and didn't fall back that much. Not too many people know who they are---they know Abbv--but ENTA has other partners like Novartis. Go with ENTA--on the ground floor.
AMGN does it again! This has been the pattern for the past 14 years. Looks like just another chronic under-performer doing what it does best... under-performing.
Zack's analyst, Jason Napadano, put a "BUY" rating on AMBS with a .20 price target. Read his articles at SeekingAlpha.
Currently trading under a nickle.
Follow the company on Twitter: @AmarantusBio .... 8,639 followers.
I got into AMGN a long time ago because ZAcks had amgn and celg on #1 and 2 ratings. Today Zacks put a cheapy IMUC on #1 rating. I think it deserves a look.
Nice long-term hold, and a hefty dividend yield to boot. Correct me if I'm wrong. but I calculate that you have just over 3,000 shares and you're receiving a tad over your initial investment amount in dividends every year.
Zack's analyst, Jason Napadano, has a "buy rating" on AMBS with a price target of .20 or about 400% upside.
Read the recent Yahoo news.
Buy a few shares and hold them for a year.
Wrong. I have 9600 shares. I don't call what AMGN pays a "hefty dividend yield." Under 2% is better than what they paid until very recently which was zilch, but it's far from "hefty." Meager is more like it. AMGN is one of my worst performing stocks. Since 2000, it has been nearly dead money compared to most of my other holdings. If it were not for the fact that I'll probably die fairly soon, and I want to avoid paying the capital gain tax, I'd have sold it.